![[Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care](https://imgproxy.divecdn.com/5lAJkli_KcGt1FSsw4EaegjgP76IHREqYEWbhNBJOXw/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9QaGFybWFEaXZlXzEzNDZfeF83MjlfQXJ0d29yay5qcGc=.webp)
NGM Bio slims down in strategic pivot, cutting 75% of staff and halting a midstage liver disease program
California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of a phase 2 liver disease asset and halting further investment in discovery and preclinical work, the company confirmed in a statement to Fierce Biotech.
California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of a phase 2 liver disease asset and halting further investment in discovery and preclinical work, the company confirmed in a statement to Fierce Biotech.
